Walgreens Boots Alliance, Inc. vs Ligand Pharmaceuticals Incorporated: A Gross Profit Performance Breakdown

Walgreens Boots Alliance vs Ligand Pharmaceuticals: A Decade of Gross Profit Performance

In the ever-evolving landscape of the pharmaceutical and retail sectors, Walgreens Boots Alliance, Inc. and Ligand Pharmaceuticals Incorporated have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, Walgreens Boots Alliance consistently demonstrated robust financial health, with gross profits peaking in 2018 at approximately $30.8 billion. This represents a steady growth of around 43% from 2014. In contrast, Ligand Pharmaceuticals, a smaller player, experienced more volatility. Its gross profit surged by over 340% from 2014 to 2018, reaching a high of $245 million, before experiencing fluctuations in subsequent years.

The data highlights the resilience of Walgreens Boots Alliance amidst market challenges, while Ligand Pharmaceuticals' performance underscores the dynamic nature of smaller biotech firms. Notably, 2024 data for Ligand is missing, suggesting potential shifts or reporting changes. This analysis offers a compelling glimpse into the financial narratives of these industry giants.